Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus VIBATIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus VIBATIV.
CHLOROMYXIN vs VIBATIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Lipoglycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Also disrupts membrane potential and increases membrane permeability.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
10 mg/kg intravenously once every 24 hours, infused over 60 minutes for 7 to 14 days.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life is approximately 177 hours (7.4 days), supporting once-daily dosing.
CHLOROMYXIN is not a recognized drug. No data available.
Primarily renal excretion as unchanged drug (approximately 93% of dose recovered in urine; <5% in feces).
Category C
Category C
Antibiotic
Antibiotic